Role of testosterone in managing advanced prostate cancer

Kyle O. Rove; Frans M. Debruyne; Bob Djavan; Leonard G. Gomella; Hari K. Koul; M. Scott Lucia; Daniel P. Petrylak; Neal D. Shore; Nelson N. Stone; E. David Crawford

doi:10.1016/j.urology.2012.05.006

Role of testosterone in managing advanced prostate cancer

Kyle O. Rove, Frans M. Debruyne, Bob Djavan, Leonard G. Gomella, Hari K. Koul, M. Scott Lucia, Daniel P. Petrylak, Neal D. Shore, Nelson N. Stone, E. David Crawford

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer. New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.

Original language	English
Pages (from-to)	754-762
Number of pages	9
Journal	Urology
Volume	80
Issue number	4
DOIs	https://doi.org/10.1016/j.urology.2012.05.006
State	Published - Oct 2012

Access to Document

10.1016/j.urology.2012.05.006

Cite this

@article{4eb92537e7024a6d86f39a46296e2942,

title = "Role of testosterone in managing advanced prostate cancer",

abstract = "Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer. New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.",

author = "Rove, {Kyle O.} and Debruyne, {Frans M.} and Bob Djavan and Gomella, {Leonard G.} and Koul, {Hari K.} and Lucia, {M. Scott} and Petrylak, {Daniel P.} and Shore, {Neal D.} and Stone, {Nelson N.} and Crawford, {E. David}",

year = "2012",

month = oct,

doi = "10.1016/j.urology.2012.05.006",

language = "English",

volume = "80",

pages = "754--762",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Role of testosterone in managing advanced prostate cancer

AU - Rove, Kyle O.

AU - Debruyne, Frans M.

AU - Djavan, Bob

AU - Gomella, Leonard G.

AU - Koul, Hari K.

AU - Lucia, M. Scott

AU - Petrylak, Daniel P.

AU - Shore, Neal D.

AU - Stone, Nelson N.

AU - Crawford, E. David

PY - 2012/10

Y1 - 2012/10

N2 - Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer. New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.

AB - Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer. New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.

UR - http://www.scopus.com/inward/record.url?scp=84866737033&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2012.05.006

DO - 10.1016/j.urology.2012.05.006

M3 - Review article

C2 - 22795376

AN - SCOPUS:84866737033

SN - 0090-4295

VL - 80

SP - 754

EP - 762

JO - Urology

JF - Urology

IS - 4

ER -

Role of testosterone in managing advanced prostate cancer

Abstract

Access to Document

Fingerprint

Cite this